Abstract
Leflunomide, a new anti-rheumatic drug, was used to treat a canine case of refractory immune-mediated thrombocytopenia that was unresponsive to conventional immunosuppressive therapy. It effectively induced remission of the thrombocytopenia and maintained a normal platelet count without adverse effects and is therefore considered an effective and safe drug for treating refractory immune-mediated hematological diseases in veterinary medicine.
